Tongjitang Chinese Medicines Company (TCM) Announces Q3 Financial Results

Tongjitang Chinese Medicines Company (NYSE: TCM) announced financial results for the quarter ended September 30, 2009. The net revenue was $15.3M and gross margin was 57.6% in Q3 compared to 62.4% in the same period of 2008. The net loss attributable to the Company was $2.0M, which yielded net loss per ADS of $0.06 and net loss per share of &$0.02.

Tongjitang Chinese Medicines Company (TCM) is a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China.